Feasibility and safety of rehabilitation for people with non-small cell lung cancer being treated with immunotherapy: a pilot randomised controlled trial.

The University of Melbourne0 个研究点目标入组 30 人开始时间: 2024年8月27日最近更新: 2024年9月2日

适应症

试验速览

暂无简介。

•People with a histologically confirmed diagnosis of stage IV, inoperable non-small cell lung cancer (NSCLC) and receiving or are planned to commence treatment with immune checkpoint inhibitors (immunotherapy) either alone or in combination with chemotherapy.
•Age > or = 18 years at screening
•Have provided written informed consent for the trial
•Able to read and write English
•Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
•Available for follow up
•Life expectancy greater than 6 months
•Able to access telehealth for exercise classes if that is their preferred method of attending (requires access to a suitable device and internet sufficient for a video call)

•Patients scheduled to receive or receiving neoadjuvant immunotherapy or chemo-immunotherapy.
•More than six months post commencement of immunotherapy
•Unstable psychiatric, cognitive or substance abuse disorders that would interfere with cooperation with the requirements of the trial
•Concurrent, actively treated other malignancy or history of other malignancy treated within the past year (other than non- melanoma skin cancer or in-situ melanoma)
•Comorbidities preventing participation in land-based exercise
•Have met the exercise guidelines for people with cancer for the past month
•Patients with a documented bone metastasis where the stability poses a risk of injury during the performance of exercise training; as assessed by the treating oncologist or orthopaedic surgeon.

发起方